Checkpoint blockade immunotherapy has had remarkable development in the last decade, and immune checkpoint inhibitor- (ICI-) targeted programmed cell death 1 (PD-1) and its ligand (PD-L1) have provided promising survival benefit for NSCLC patients [2]. Here, PDCD1 is linked to non-small cell lung carcinoma.